FIELD: medicine.
SUBSTANCE: group of inventions is intended for treating hepatic fibrosis or renal fibrosis in a subject having indications for this purpose. That is ensured by administering jointly to a subject a therapeutically effective amount of the pharmaceutical composition, containing Cenicriviroc or salt or solvate thereof, and one or more additional active agents selected from a group consisting of oieticholic acid, pioglitazone, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl] benzoic acid (GW4064), 2-methyl-2-[[4-[2-[[(cyclohexylamino)carbonyl](4-cyclohexylbutyl)amino]ethyl]phenyl]thio] propanoic acid (GW7647), 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)propenyl]phenoxyl]-2-methylpropanoic acid (GFT505) and BX471. Said hepatic fibrosis is associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), non-cirrhotic hepatic fibrosis or hepatic cirrhosis. Also provided is a method of treating NASH in a subject having indications for this, comprising co-administering a therapeutically effective amount of the pharmaceutical composition to a subject, containing Cenicriviroc or its salt or solvate, wherein NASH is associated with type 2 diabetes mellitus (DM2), metabolic syndrome (MS) or HIV and HCV coinfection, and one or more additional active agents selected from a group consisting of oieticholic acid, pioglitazone, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl] benzoic acid (GW4064), 2-methyl-2-[[4-[2-[[(cyclohexylamino)carbonyl](4-cyclohexylbutyl)amino]ethyl]phenyl]thio] propanoic acid (GW7647), 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)propenyl]phenoxyl]-2-methylpropanoic acid (GFT505) and BX471.
EFFECT: using the group of inventions enables providing higher clinical effectiveness in liver and renal fibrosis, as well as NASH in a subject.
23 cl, 24 tbl, 43 dwg, 19 ex
